Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 1083-1086

  Steinbach, Daniel ^a   Lengemann, Janka ^a   Voigt, Astrid ^a   Hermann, Johann ^a   Zintl, Felix ^a   Sauerbrey, Axel ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MITOCHONDRIAL PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RECURRENCE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037342747     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Creutzig, U., Ritter, J., Zimmermann, M., Hermann, J., Gadner, H., Sawatzki, D. B., Niemeyer, C. M., Schwabe, D., Selle, B., Boos, J., Kaehl, J., and Feldges, A. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia, 15: 348-354, 2001.
2. Stevens, R. F., Hann, I. M., Wheatley, K., and Gray, R. G. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br. J. Haematol., 101: 130-140, 1998.
3. Wood, P., Burgess, R., MacGregor, A., and Yin, J. A. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br. J. Haematol., 87: 509-514, 1994.
4. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O. A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H., and Lechner, K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl, Cancer Inst. (Bethesda), 83: 708-712, 1991.
5. List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., Shurafa, M., and Appelbaum, F. R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood, 98: 3212-3220, 2001.
6. Tidefelt, U., Liliemark, J., Gruber, A., Liliemark, E., Sundman-Engberg, B., Juliusson, G., Stenke, L., Elmhorn-Rosenborg, A., Mollgard, L., Lehman, S., Xu, D., Covelli, A., Gustavsson, B., and Paul, C. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J. Clin. Oncol., 18: 1837-1844, 2000.
7. Sievers, E. L., Smith, F. O., Woods, W. G., Lee, J. W., Bleyer, W. A., Willman, C. L., and Bernstein, I. D. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Children's Cancer Group. Leukemia (Baltimore), 9: 2042-2048, 1995.
8. Steinbach, D., Furchtbar, S., Sell, W., Hermann, J., Zintl, F., and Sauerbrey, A. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML, Leukemia, 17: 470-471, 2003.
9. Marie, J. P. Drug resistance in hematologic malignancies. Curr. Opin. Oncol., 13: 463-469, 2001.
10. Borst, P., Evers, R., Kool, M., and Wijnholds, J. A. family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. (Bethesda), 92: 1295-1302, 2000.
11. Kruh, G. D., Zeng, H., Rea, P. A., Liu, G., Chen, Z. S., Lee, K., and Belinsky, M. G. MRP subfamily transporters and resistance to anticancer agents. J. Bioenerg. Biomembr., 33: 493-501, 2001.
12. Laupeze, B., Amiot, L., Drenou, B., Bernard, M., Branger, B., Grosset, J. M., Lamy, T., Fauchet, R., and Fardel, O. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br. J. Haematol., 116: 834-838, 2002.
13. Legrand, O., Simonin, G., Perrot, J. Y., Zittoun, R., and Marie, J. P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood, 91: 4480-4488, 1998.
14. , Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J., Grever, M. R., Appelbaum, F. R., and Willman, C. L. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein. MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94: 1086-1099, 1999.
15. van der Kolk, D. M., de Vries, E. G., van Putten, W. J., Verdonck, L. F., Ossenkoppele, G. J., Verhoef, G. E., and Vellenga, E. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin. Cancer Res., 6: 3205-3214, 2000.
16. Filipits, M., Suchomel, R. W., Zochbauer, S., Brunner, R., Lechner, K., and Pirker, R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res., 3: 1419-1425, 1997.
17. van der Kolk, D. M., de Vries, E. G., Noordhoek, L., van den Berg, E., van der Pol, M. A., Muller, M., and Vellenga, E. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia, 15: 1544-1553, 2001.
18. Steinbach, D., Dorffel, W., Eggers, G., Holfeld, E., Kluba, U., Krause, I., Lauterbach, I., Reiss, T., Rieske, K., Scharfe, V., Schumacher, R., Weigel, H., Weinmann, G., Zintl, F., and Hermann, J. Improved results in the treatment of acute myeloid leukemia: results of study AML-BFM-93 in East Germany with comparisons to the preceding studies AML-I-82 and AML-II-87. Klin. Padiatr., 213: 162-168, 2001.
19. Yoshida, M., Suzuki, T., Komiya, T., Hatashita, E., Nishio, K., Kazuhiko, N., and Fukuoka, M. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. Int. J. Cancer, 94: 432-437, 2001.
20. Steinbach, D., Sell, W., Voigt, A., Hermann, J., Zintl, F., and Sauerbrey, A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia (Baltimore), 16: 1443-1447, 2002.
21. Sirotnak, F. M., Wendel, H. G., Bornmann, W. G., Tong, W. P., Miller, V. A., Scher, H. I., and Kris, M. G. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin. Cancer Res., 6: 3705-3712, 2000.
22. Young, L. C., Campling, B. G., Cole, S. P., Deeley, R. G., and Gerlach, J. H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res., 7: 1798-1804, 2001.